Introduction
============

Since the discovery of omega-3 (ω3) PUFAs in 1929 by George Burr and Mildred Burr ([@B22]; [@B206]), research on ω3 PUFAs became an appealing topic ranging from their role in cardiovascular risk to more recently neuropsychiatric pathologies such as depression and anxiety, cognitive decline or neurodegenerative diseases ([@B11]; [@B104]; [@B42]). The relevance of lipids in brain function is illustrated by the fact that the CNS has the highest concentration of lipids in the organism after the adipose tissue (50--60% of the dry weight of the brain; [@B194]). Among these lipids, the brain is particularly greedy for PUFAs from the ω6 and ω3 PUFAs families, in particular the LC PUFA (AA, 20:4n-6) and (DHA, 22:6n-3), respectively ([@B194]). In the Human brain, DHA accounts for 10 to 15% of the total fatty acids (saturated, monounsaturated and PUFAs) in both males and females ([@B149], [@B151]). This makes PUFAs indispensable to the normal development and function of the CNS ([@B137]; [@B100]; [@B11]). One hypothesis explaining this abundance in brain tissue is that *Homo sapiens* in Paleolithic settled around the lakes and seas where access to foods rich in ω3 PUFAs is easy ([@B18]). It is generally considered that humans evolved on a diet with a ratio of ω6 to ω3 PUFAs equal approximately to 1. During the industrial era, the rapid expansion of Western countries has been associated with drastic changes in the ω6/ω3 PUFAs content of the diet. This is reflected in large quantities of ω6 PUFA-containing foods and smaller amounts of ω3 PUFA-rich foods leading to Western diet being typically poor in ω3 PUFAs. In addition, the intake of saturated fats from lard and butter has been replaced by plant-based PUFAs based on recommendations from health agencies ([@B78]). As a result, the use of oils such as sunflower oil which are mostly high in (LA, the precursor of AA) and low in a-linolenic acid (ALA, the precursor of DHA) leads to a marked increase in LA intake. In mammals, LA and ALA cannot be synthesized *de novo* and need to be provided through the diet ([@B204]; [@B77]). These essential PUFAs are metabolized into LC PUFAs using the same enzymatic pathway, meaning that LA and ALA are in competition for endogenous conversion to their respective LC forms AA, and DHA (**Figure [1](#F1){ref-type="fig"}**) but also for their entry into the brain ([@B11]). Of importance, ALA bioconversion into DHA through several cycles of elongation (ELOVLs) and desaturation (Δ5 and Δ6 desaturases) is in the range of 0.05% ([@B21]) to 4% ([@B62]) and might not be sufficient to cover brain needs. This led to the recommendation of dietary intake of oily fish rich in the LC ω3 PUFAs DHA and EPA ([@B215]). Overall, western diets which are rich in LA (coming from vegetable oils rich in LA) and poor in ALA and DHA (coming from fat fish, sea food or certain algae) have created "a conditional essentiality for ω3 PUFAs" as previously described by [@B44] and [@B78]. Indeed, the amount of LC ω3 PUFAs needed to compensate this lack in western diet is likely to increase, which is not sustainable in the actual context of fish stock decline ([@B66]).

![Long-chain PUFAs synthesis. Essential fatty acids precursors of n-6 and n-3 PUFAs are provided by food. Once in the livers, they are metabolized into long-chain PUFAs using a series of desaturations and elongation machinery. The newly synthetized long-chain n-6 PUFAs are AA (20:4n-6) and DPA (22:5n-6) and the long-chain n-3 PUFAs are DHA (22:6n-3) and DPA (22:5n-3).](fphys-09-01047-g001){#F1}

The reduced dietary supply of ω3 PUFAs to the brain is associated with many brain diseases, including depression and anxiety disorders (see review from [@B164]). Epidemiological studies have linked low ω3 PUFAs dietary intake with the prevalence of depression in the general population ([@B88]). Clinical studies further revealed that subjects diagnosed with depression or anxiety display significant lower levels of ω3 PUFAs and higher ratio of ω6 to ω3 PUFAs in the blood and in the brain ([@B83]; [@B153]; [@B178]). Supporting clinical observations, preclinical studies conducted in rodents showed that ω3 PUFA deficient diet consumption induces depressive- and anxiety-like symptoms as well as abnormal social behavior in adult offspring ([@B116]; [@B120], [@B119], [@B118]; [@B14]). Importantly, the use of dietary animal models has been crucial to study the neurobiological mechanisms underlying the alteration of emotional behaviors following decreased bioavailability of ω3 PUFAs in the brain. In this review, we first discuss clinical and pre-clinical evidence of the importance of ω3 PUFAs in anxiety and depressive disorders as well as the rationale for evaluating baseline levels of ω3 PUFAs prior to starting nutritional intervention studies. Then we describe mechanisms linking ω3 PUFAs and emotional behaviors disturbance, especially the sensing activity of FFAR, the eCB system, glucocorticoids as well as neuroinflammatory pathways.

The Role of ω3 Pufas in Depression and Anxiety Disorders
========================================================

Clinical and Epidemiological Evidence Linking ω3 PUFAs, Depression and Anxiety
------------------------------------------------------------------------------

Several clinical and epidemiological studies highlighted the link between mood disorders and blood and/or cellular membrane PUFAs content (reviewed in [@B164]). These observations led to the "phospholipids hypothesis" according to which PUFAs are possible aetiological factors in the development of depressive disorders ([@B91]). Indeed, subjects diagnosed for anxiety and depressive disorders show lower ω3 PUFAs and higher ratio of ω6 to ω3 PUFAs in their blood and brains compared to healthy subjects matching for age and sex ([@B1]; [@B136]; [@B60],[@B61]; [@B217]; [@B71]; [@B83]; [@B149]; [@B153]; [@B178]). EPA (20:5 n-3) concentration ([@B1]; [@B83]; [@B130]) as well as DHA concentration ([@B60]; [@B71]; [@B83]; [@B153]; [@B130]; [@B174]) are decreased in the membrane of erythrocytes and in the plasma of patients suffering from unipolar depression, seasonal winter affective disorder or social anxiety disorders ([@B1]; [@B83]). A recent study showed that the AA:EPA ratio in the blood is positively correlated with illness duration in patients diagnosed with major depression ([@B197]). A meta-analysis work from [@B129] supports these observations by showing significant low levels of EPA, DHA, and total ω3 PUFAs among 3,318 depressed patients. In some of these studies, the severity of the depressive and anxious symptoms is negatively correlated with the concentration of the total ω3 PUFA levels in the blood ([@B1]; [@B136]; [@B60]; [@B83]; [@B130]). Post-mortem studies report reduced levels of DHA in the PFC of patients diagnosed with major depression, bipolar disorders or committing suicide ([@B149], [@B150], [@B152]). In pregnant women, for whom the risk of ω3 PUFAs deficiency is relatively high as they provide DHA to the fetus, nearly 10% experience post-partum depression ([@B141]). Yet, no clear consensus exist as to whether low ω3 PUFAs and high ω6 PUFA levels in the blood are linked to the development of post-partum depression ([@B89]; [@B177]). These observations are not limited to depression as decreased ω3 PUFAs (DHA) levels in erythrocytes and PFC have also been found in patients suffering from PTSD ([@B48]). As decreased ω3 PUFAs status is associated with several forms of depression and stress disorders, the understanding of the origin (dietary or genetic) of the decreased bioavailability of DHA or EPA is of high interest.

The rationale for identifying baseline nutritional ω3 PUFAs status comes from one hypothesis advanced by researchers that weak food supply in ω3 PUFAs might be a risk factor of the development of depression. As fish is the main source of LC ω3 PUFAs, several epidemiological studies investigating putative associations between major depressive disorder and fish consumption were conducted in various countries (Finland, New Zealand, France, Northern Ireland, Norway or Netherlands) ([@B214]; [@B203]; [@B218]; [@B9]; [@B106]; [@B4]; [@B183]; [@B41]). Subjects having low fish consumption (lower than once per week, including seafood) present high scores of depression ([@B218]; [@B9]). A transnational ecological study conducted on a large cohort including individuals from different countries highlighted a strong negative correlation between fish consumption and the prevalence of depression ([@B88]). Indeed, this epidemiological study of great width (170,000 individuals) revealed that individuals from Asian countries like Japan, Korea, and Taiwan, who are the biggest fish consumers, suffer relatively little from major depression. This observation can appear counterintuitive as Japan experiences a high rate of suicide while the depression rate is thought very low ([@B223]). Such a high rate of suicide has been associated to cultural factors (idealization of suicide, acceptability, etc.) including aging society ([@B191]), divorce and unemployment ([@B229]). On the contrary, Western countries like New Zealand, Canada, United States, Germany, or France are part of the countries that consume less fish with high prevalence to develop depression. These data suggest that fish consumption is conversely correlated with the development of depression.

To PUFA dietary intake consideration in decreasing ω3 PUFAs bioavailability in depression, one must add the genetic variation of the FADS, an enzyme which converts PUFA precursors into LC-PUFAs (EPA, DHA, and AA) ([@B110]; [@B144]; [@B176]). Indeed, inter-individual variability in red blood cells DHA and AA levels is explained by FADS polygenes (71 and 53%, respectively) ([@B123]). FADS genotypes influence DHA amounts in red blood cells of pregnant women independently of dietary effects ([@B110]). Children carrying FADS minor allele have lower DHA levels in erythrocyte, with no behavioral outcomes ([@B103]). However, the link between FADS haplotype and the risk of developing neuropsychiatric disorders (schizophrenia or depression) is weak ([@B63]; [@B196]). A study conducted in patients with major depression found no association between FADS single nucleotide polymorphisms and major depression ([@B209]). Recently, a study suggested that genetic variation in the FADS gene influences the ω6/ω3 PUFAs ratio which appears to be associated with major depression ([@B43]). To our knowledge, no study has so far linked brain DHA level to FADS genotype. Overall, in addition to dietary composition of PUFAs, FADS genetic variation should be considered in the LC-PUFAs status and the pathophysiology of depression and stress.

Taken together, these clinical observations raise a crucial question: Is there a causal link between the contents of ω3 PUFAs in the blood/brain and depressive/anxiety disorders? If so, are the low levels of ω3 PUFAs the cause or the consequence of these affective disorders? These relations of causalities were approached by nutritional interventions in Humans which are the object of the following section, first in depression, then in PTSD and stress disorders.

Dietary ω3 PUFAs Supplementation, Depression, and PTSD in Humans
----------------------------------------------------------------

The results from LC ω3 PUFA nutritional interventions carried out among patients with depressive disorders are heterogeneous as recently reviewed elsewhere ([@B17]; [@B195]). Some studies conducted on patients suffering from major depression without an antidepressant treatment do not show significant effects of ω3 PUFAs supplementation ([@B139]; [@B72]; [@B186]; [@B159]), whereas others reveal a beneficial effect ([@B207]; [@B169]; [@B102]). A 16-week dietary supplementation with EPA + DHA did not prevent maternal depressive symptoms ([@B221]). These discrepancies are reflected by meta-analysis. Indeed, some found that EPA and DHA can reduce depressive symptoms ([@B111]; [@B5]; [@B208]; [@B84]) while other found no effect ([@B6]). Mixed results of clinical trials could be attributed not only to the heterogeneity in clinical trials and design, but also to the quantity and quality of the PUFA used, including the EPA:DHA ratio, trial duration, the type of placebo (PUFA or other fatty acids) and to the concomitant use of medication and baseline symptom severity. Recently, EPA, rather than DHA, has been suggested to mediate the beneficial effect of ω3 PUFAs supplementation in patients diagnosed with major depression DHA ([@B142]; [@B143]; [@B84]; [@B85]). Indeed, several studies using ethyl-EPA (from 1 to 2 g/day) reported a beneficial effect in patients with major depression and resistant to anti-depressant ([@B180]) or recurrent unipolar depression ([@B168]). In addition, EPA-rich formulation with no DHA is more effective than DHA-rich supplements in major depression ([@B208]). A meta-analysis aiming at investigating the beneficial role of EPA or DHA supplementation in major depressive disorder found that EPA is more effective than DHA ([@B84]). The beneficial effect of EPA has been recently corroborated by a new meta-analysis ([@B160]). EPA efficiency could be linked to its conversion into DHA by elongase leading to increased DHA brain bioavailability and decreased LC ω6 PUFAs production ([@B75]). Indeed, as the conversion of EPA into DHA compete with the production of n-6 DPA from AA by using the same enzymatic pathway (i.e., FADS and elongases), the supplementation of EPA can simultaneously lead to an increase in DHA and a decrease in n-6 DPA levels that can subsequently improve mood. However, further studies with larger and more homogeneous samples are required to confirm these effects.

In addition, it has been suggested that depressive patients who display low levels of ω3 PUFAs may rather benefit of the LC ω3 PUFAs supplementation ([@B31]; [@B157]). Despite recent advances in understanding the pathophysiology of major depression, approximately 30% of patients remain refractory to multistep antidepressant treatments ([@B189],[@B190]). One explanation of this finding could come from individual differences in baseline levels of ω3 PUFAs. To support this idea, a study recently showed that high baseline levels of EPA and DHA in red blood cells of depressive patients predict favorable depression outcomes in patients receiving ω3 PUFAs supplements ([@B31]). In addition, among patients treated but resistant to antidepressants such as the (SSRI; e.g., Fluoxetine, Paroxetine), the severity of the symptoms of depression decreased in the group supplemented in ω3 PUFAs ([@B168]; [@B180]; [@B207]; [@B102]; [@B76]; [@B232]; [@B154]; [@B160]). This strategy can be highly relevant as resistance to treatment is observed in a large proportion of patients (40%) ([@B20]; [@B201]) and it suggests that dietary ω3 PUFA intake may improve antidepressant response.

ω3 PUFAs dietary supplementation has also been used in stress disorders. Stress is a well-known major risk factor for the development of depression or PTSD. One study aimed at investigating the effect of ω3 PUFAs supplementation in chronically work-stressed individuals and found no significant treatment effect for EPA after 12 weeks of supplementation on the Perceived Stress Scale scores ([@B19]). On the contrary, a placebo-controlled trial of ω3 PUFAs supplements in patients suffering from PTSD revealed that EPA but not DHA ([@B145]) levels were inversely correlated with PTSD severity suggesting the potential efficacy of EPA rather than DHA for minimizing PTSD symptoms ([@B146]). Regarding ω3 PUFAs supplementation in the prevention of anxiety, a study conducted by [@B230] has investigated whether administration of a cocktail of ω3 PUFAs (90 mg of ALA/day) and ω6 PUFAs (360 mg of LA/day) over 3 weeks in students could improve anxiety induced by the university examinations. These authors highlighted an improvement of several symptoms (appetite, mood, concentration, and fatigue) compared to the placebo group. These improvements are associated with a decreased level of salivary cortisol ([@B230]). Despite the low dose of ALA used in this study (90 mg/day) as compared to nutritional intake in the general population (1--2 g/day), this 10% increase was sufficient to improve symptoms. In addition, ALA conversion in EPA is determined by the amount of ALA in the diet (i.e., higher in the plasma phospholipid pool when ALA is low) ([@B82]). Thus, the effectiveness of ALA in [@B230] study could be linked to EPA. Moreover, students having received a supplementation with DHA and EPA during 12 weeks present a reduction of 20% of anxiety symptoms compared to the students treated with a placebo ([@B109]). In students treated with ω3 PUFAs supplementation, an increase in plasma concentration of DHA and EPA were observed as of the third week of treatment. Lastly, the increase in DHA and EPA was negatively correlated with a reduction in anxiety symptoms.

In conclusion, these observations further support the role of PUFAs metabolism as an important mechanism in depression and anxiety disorders treatment. This brings new insight to personalized PUFAs formulation as a novel adjunctive treatment for patients with mood and anxiety disorders.

Pre-clinical Studies Linking ω3 PUFAs and Emotional Behavior
------------------------------------------------------------

To better understand whether the modifications of nutritional ω6/ ω3 PUFA ratio could affect brain function and behavior, studies have been carried out in animals (rodents, monkeys, and pigs) subjected to diets in which PUFAs contents are controlled during one or several generations ([@B46]; [@B40]). Numerous studies have shown that in animal models of nutritional ω3 PUFA deprivation, brain DHA levels were decreased while AA levels were increased in several brain areas leading to an imbalance between ω6 and ω3 PUFAs in the ω3 PUFAs deficient mouse brain ([@B51]; [@B70]; [@B64]; [@B33]; [@B148]; [@B116]; [@B120]). Nutritional ω3 PUFAs deficiency-induced reduction of brain DHA levels has been associated with the development of depression-like behavior ([@B32]; [@B213]; [@B54]; [@B65]; [@B116]; [@B120], [@B119], [@B118]; [@B14]; [@B163]; [@B138]). By submitting mice to one generation dietary ω3 PUFAs deficiency, we found that ω3 PUFAs deficient diet alone disturbed social behavior as well as increased anxiety- and depression-related behavior in an open-field and FSTs, respectively ([@B116]; [@B120], [@B119], [@B118]). Some studies conducted in rats indicate that the time of immobility in the FST was increased by ω3 PUFAs deficiency ([@B54]; [@B163]) and reduced by ω3 PUFAs supplementation with fish oil ([@B166]; [@B30]; [@B98]). In addition, the level of DHA in rat whole brains is negatively correlated with the time spent immobile during the FST, a behavioral test used for evaluating the efficacy of compounds rendering or preventing depressive-like states. Interestingly, similar behavioral impairments (e.g., anxiety-like behavior and social interaction) occur in mice after exposure to CSDS, a well-characterized preclinical model of anxiety and depression ([@B80]; [@B15]; [@B117]). This model presents strong face validity, as social defeat (e.g., bullying) is a major risk factor to developing depression in humans. One cardinal feature of CSDS is that mice experiencing this chronic stress develop a long-lasting (more than 1 month) aversion to social interaction as well as anhedonia, which can be normalized after chronic (28 days post-CSDS), but not acute administration of antidepressant ([@B13]; [@B112]) as observed in humans. By comparing the effects of dietary ω3 PUFAs deficiency to those of CSDS on emotional behavior, We found that mice fed with a diet deficient in ω3 PUFAs exhibited behavioral changes and neuronal atrophy profile that resemble those of mice exposed to CSDS ([@B119]). Interestingly, behavioral alterations can be reversed after chronic ω3 PUFAs supplementation. As such, increased anxiety- and depressive-like behavior after chronic stress is normalized after ω3 PUFAs supplementation ([@B67]; [@B119]).

Relevant Mechanisms for Nutritional ω3 Pufa-Induced Mood-Related Behavioral Deficits
====================================================================================

Numerous epidemiological, clinical, and preclinical studies demonstrated the key role of nutritional ω3 PUFAs in depression and anxiety disorders. In recent years, emphasis was made on identifying molecular and cellular mechanisms by which ω3 PUFAs modulate brain function. ω3 PUFAs and their metabolites are well known to play an important role as signaling molecules that regulate inflammation ([@B198]) and neuroinflammation (recently reviewed in [@B121]). They also contribute to signal transduction between neurons or neurons and glial cells. Here, we will focus on DHA, the most aggregated fatty acid in the brain while EPA is rapidly b-oxidized and poorly accumulated ([@B36]). As DHA is poorly synthesized *de novo*, its brain levels depend on both the dietary supply and blood level bioavailability ([@B11]; [@B115]). Once free DHA has entered the brain, it is esterified at membrane phospholipids (both in neurons and glial cells). However, upon neuronal stimulation, injury or stress, DHA is released from phospholipids and can either activate specific receptors or be metabolized into specific derivatives, such as eCBs or oxylipins which regulate specific pathways important to neurotransmission or neuroinflammation ([@B11]; [@B16]; [@B121]). In the following section, we first describe the receptors which have been reported to mediate DHA effect in the brain. Then, we focus on the regulation of the eCB system and the HPA axis as recent data show that they could mediate the neuroprotective effect of ω3 PUFAs as both are thought to be involved in depression.

Direct Effect of DHA on Specific Receptors
------------------------------------------

While free fatty receptors have been widely described to mediate some of the effects of DHA at the periphery, few reports highlight a direct effect of DHA through signaling activity in the brain. In 2000, DHA has been shown to be a ligand of the RXR, the receptor of retinoic acid (a vitamin A metabolite), which heterodimerizes with other nuclear receptors such as retinoic acid receptor, vitamin D receptor, thyroid hormone receptor or PPAR ([@B124]). DHA effect on neuritogenesis does not involve RXR, as its effect *in vitro* does not activate RXR ([@B25]). However, DHA potentiates retinoic acid effect and improves cognitive symptoms in a rodent model of Alzheimer disease ([@B34]) and aged rodents ([@B126]). Interestingly, the loss of RXR signaling leads to altered emotional and cognitive behavior in mice ([@B113]; [@B224]). Importantly, DHA antidepressant effect is absent in RXR knock-out mice ([@B224]), further highlighting the role of this receptor and its ligand (possibly DHA and retinoic acid) in emotional behavior. FFAR, members of the "rhodopsin-like" GPCR family, namely GPR40 (FFAR1) and GPR120 (FFAR4), have been recently highlighted as potentially mediating LC FFAs signal from pancreatic beta-cells as well as the intestines ([@B101]; [@B93]). These lipid receptors were also reported to be present in the brain ([@B133]; [@B58]). Memory-induced progenitor cell proliferation and DHA-induced neurogenesis in the hypothalamus are mediated by GPR40 ([@B132]; [@B228]; [@B167]). In addition, DHA-induced GPR40 signaling pathway activates β-endorphin release in the hypothalamus of rodents ([@B165]). Importantly, the chronic activation of GPR40 signaling in the brain reduces depressive-like behavior ([@B172]). In addition, anxiety-like behavior and sucrose preference, a behavioral sign of anhedonia, are reduced in GPR40 knock-out mice further highlighting the role of GPR40 signaling in the pathophysiology of mood disorders ([@B2]). GPR120, another GPR which signals DHA activity, is highly expressed in the arcuate nucleus of the hypothalamus and the NAc, a structure involved in emotional behavior ([@B7]). Interestingly, GPR120 activation by a specific agonist reduces obesity-induced emotional behavior alteration ([@B7]). Taken together, these data suggest that several receptors could mediate a direct effect of DHA on neurons to control emotional behavior, opening new avenues in drug development targeting these receptors. However, additional studies are needed to determine whether DHA acts through these receptors to protect from depression and anxiety disorders in humans.

Endocannabinoid System
----------------------

Regulation of the eCB system could mediate the neuroprotective effect of ω3 PUFAs as both are thought to be involved in depression. The eCB system is in a unique position to link food lipids, neuroplasticity and behavior ([@B11]; [@B16]; [@B38]). eCBs are signaling lipids produced from membrane LC fatty acid in response to neuronal activity and they bind the GPCR CB1R ([@B134]) (**Figure [2](#F2){ref-type="fig"}**). eCBs are produced on-demand and are rapidly degraded, back into PUFAs or oxidized into active metabolites ([@B16]). eCBs include the fatty acid AEA, DHEA, oleylethanolamide and palmitoylethanolamide, as well as 2-AG ([@B182]). The two principal eCBs, AEA and 2-AG, are AA-derived metabolites, while DHEA is derived from the DHA and oleylethanolamide and palmitoylethanolamide is derived from EPA. The most well-studied eCBs are the ω6 PUFA-derived AEA ([@B55]) and the 2-AG ([@B210]) as compared to the ω3 PUFA-derived eCBs. Activation of CB1 receptors inhibits AC activity leading to a subsequent reduction in the cAMP cascade, augmentation of potassium channels, and inhibition of subsequent calcium influx via calcium channels (**Figure [2](#F2){ref-type="fig"}**) ([@B97]; [@B96]). Consequently, the activation of the CB1R inhibits the release of both excitatory (glutamate) and inhibitory GABA neurotransmitters from presynaptic neurons ([@B226], [@B225]; [@B73]) (**Figure [2](#F2){ref-type="fig"}**). Finally, numerous important studies have unraveled the key role of eCB system in mood regulation ([@B162]; [@B92]). As eCBs are derived from ω6 and ω3 PUFA precursors, we hypothesized that the effects of PUFAs on mood-related behavior might be mediated, at least partly, through the eCB system ([@B116]; [@B15]; [@B138]). As such, inadequate PUFAs ratio during critical time window, i.e., gestation or lactation can lead to changes in eCBs contents in the brain. Newborn piglets that were fed with a diet containing ALA, AA and DHA during the first 18 days of life showed an expected increase of AA and DHA levels in the brain but also of AEA and DHEA metabolites ([@B12]). Watanabe et al. reported that nutritional ω3 PUFAs deficiency for 2 generations elevates the levels of 2-AG in the mouse brain while ω3 PUFAs supplementation reduces them. In this study, DHA brain levels were affected by dietary ω3 PUFAs deficiency, but not AA the precursor of 2-AG which remained unchanged as compared to the control diet group ([@B222]). It is now well documented that AA levels are barely impacted by PUFAs content of the diet while DHA brain levels are more sensitive to dietary ω6/ω3 PUFAs. Whether increased 2-AG and AEA after exposure to a diet rich in ω6 PUFAs is a compensatory effect to buffer AA concentrations remains to be determined. Lastly a 2-week-supplementation in DHA increased the DHEA and decreased the AEA in brain homogenates in both rats and mice ([@B227]). One *in vitro* study also demonstrated that unesterified free DHA could directly regulate CB1 gene expression in hippocampal neurons ([@B175]). Collectively, these reports support the hypothesis proposing that nutritional PUFAs intake is tightly linked to brain eCB levels. By regulating levels of eCBs in the brain, PUFAs have been shown to impact hippocampal synaptic plasticity ([@B216]) and eCB-dependent plasticity ([@B116]; [@B138]) as well as CB1-associated signaling pathways ([@B120]) in the PFC and NAc. In mice, perinatal exposure to dietary ω3 PUFA deficiency, which leads to low DHA levels in the PFC and the NAc, abolished the eCB-long-term depression in these brain structures. Specifically, this alteration is mediated by an uncoupling from CB1R to its G protein ([@B116]). Moreover, the effect of the CB1 agonist WIN55,212-2 in anxiety-like behavior was abolished and the CB receptor signaling pathways were altered in the PFC and hypothalamus of ω3 PUFA-deficient mice ([@B120]). A recent study has involved the 2-AG in these aforementioned alterations. Our recent work highlighted that the inhibition of 2-AG degradation normalized emotional behavior deficits and eCB-dependent synaptic plasticity alteration observed in ω3 PUFA-deficient adult mice ([@B138]). These observations are the first synaptic and molecular evidence that malnutrition related to ω6/ ω3 PUFAs ratio can have detrimental effect on eCB system, subsequently leading to impaired behavior.

![PUFAs are key actors in the regulation of endocannabinoid system. Endocannabinoids are signaling lipids produced from membrane long-chain fatty acid in response to neuronal activity that bind the G-protein-coupled receptor (GPCR) CB1R. The two principal eCBs, AEA and 2-AG, are AA-derived metabolites while DHEA derived from the DHA. eCBs are released into the synaptic cleft and then bind the CB1R on the presynaptic neuron. Activation of CB1R inhibits adenylyl cyclase (AC) activity leading to a subsequent reduction in the cyclic adenosine monophosphate (cAMP) cascade, augmentation of potassium channels, and inhibition of subsequent calcium influx via calcium channels. Consequently, the activation of the CB1R inhibits the release of both excitatory (glutamate) and inhibitory (GABA) neurotransmitters from the presynaptic neuron and decreases synaptic plasticity. The stimulation of CB1R by CB agonists (THC, WIN55,212-2, and CP-55940) or eCBs also activate MAPK signaling pathway. Both eCB-dependent plasticity and CB1R-dependent signaling pathway in brain areas involved in mood-regulation are altered in mice that chronically fed an omega-3 deficient diet.](fphys-09-01047-g002){#F2}

Hypothalamic--Pituitary--Adrenal Axis
-------------------------------------

Stress and high trait anxiety are a major risk factor for neuropsychiatric diseases, particularly major depression and anxiety disorders, and are etiologically causal in PTSD ([@B193]). Interestingly, although several mechanisms underlying the effects of dietary ω3 PUFA deficiency on emotional behavior have been described (e.g., eCB system), those specifically related to HPA axis function remain poorly understood. Nevertheless, clinical data reported that low plasma DHA levels correlate with higher cerebrospinal fluid CRH levels ([@B90]) and with higher cortisol in plasma ([@B171]; [@B161]). Healthy men receiving supplementation for 3 weeks with dietary fish oil display a blunted cortisol response after an acute mental stress ([@B50]). Mood-related deficits observed in deficient mice or rats were recently linked to disrupted GR-mediated signaling pathway, HPA axis hyperactivity as well as eCB system impairment, all involved in mood regulation ([@B67]; [@B116]; [@B119], [@B118]; [@B15]). Rats that were fed with a ω3 PUFA deficient diet display HPA axis hyper-reactivity after stress exposure reflected by increased levels of plasma corticosterone compared to control diet group ([@B127]). Conversely, corticosterone hypersecretion induced by a chronic stress and IL-1β exposure is dampened in ω3 PUFA supplemented rats ([@B205]; [@B67]). In [@B163], increased hypothalamic CRF release as well as increased plasmatic corticosterone levels has been shown in ω3 PUFA deficient rats, further demonstrating the link between HPA axis hyperactivity and dietary ω3 PUFAs. In a recent study, we demonstrated that anxiety- and depressive-related behaviors as well as neuronal atrophy in the medial PFC observed in mice fed with a diet deficient in ω3 PUFAs are both mediated by HPA axis hyperactivity ([@B119]). ω3 PUFAs supplementation beyond weaning prevents chronic stress-induced increases in plasma corticosterone levels ([@B67]; [@B119]; [@B156]), PFC neuronal shrinkage ([@B119]) as well as anxiety- and depressive-like behaviors ([@B67]; [@B119]). In another study, we confirmed and followed up on their initial observations by demonstrating that GR signaling pathway is compromised in the PFC of ω3 PUFA-deficient mice along with dendritic arborization atrophy ([@B118]). The modulation of neuronal morphology by ω3 PUFAs might be not a generalized phenomenon since neuronal arborization atrophy is only observable in the PFC but not the CA1 of the hippocampus of ω3 PUFA-deficient mice ([@B53]; [@B118]). To further establish the link between dietary ω3 PUFAs consumption and neuronal morphology, *in vitro* studies were conducted showing that PUFAs activate neurites formation and growth in hippocampal ([@B24]; [@B26]) and cortical neurons ([@B27]) in primary culture. Moreover, in these same cultures, a decrease of DHA leads to the reduction of the size of neurites ([@B99]; [@B74]; [@B24]; [@B26]). The accretion of DHA in the brain considerably facilitates the formation of the dendritic spines in the hippocampus of Gerbils that were fed with a diet supplemented in DHA ([@B192]). Interestingly, genetically modified Fat-1 mice that are able to catalyze the conversion of ω6 into ω3 PUFAs display a higher density of spines in the hippocampus compared to WT mice ([@B107]; [@B87]). Moreover, increased spine density in the hippocampus of Fat-1 mice is associated with better cognitive performances assessed in Morris water maze along with increased adult neurogenesis ([@B87]). The protective effect of LC ω3 PUFAs could be linked to hippocampal neurogenesis (recently reviewed in ([@B231]). As such, changes in hippocampal neurogenesis and cell survival in the dentate gyrus have been correlated with depressive-like behavior. A recent study demonstrated that clamping glucocorticoid levels prevent CSDS-induced decreases in neurogenesis and depressive-like behavior in wild type mice, but not in mice with a genetic ablation of neurogenesis ([@B122]). This is particularly relevant knowing that LC ω3 PUFAs supplementation prevents CSDS-induced HPA axis dysregulation ([@B119]). However, whether the beneficial effect of ω3 PUFAs on glucocorticoids and mood is dependent on neurogenesis remains to be evaluated. Finally, an elegant study showed that EPA but not DHA increases neural stem cell proliferation reflected by an increased number of neurospheres bulk via CB1R activity ([@B59]). The findings that ω3 PUFAs alone modulate neuronal arborization as well as adult neurogenesis highlight the role of PUFAs as a potent modulator of brain health. Taken together, these studies provide strong validity of nutritional ω3 PUFA-deficient diet as one of the many faces of stress that deeply affects GR-dependent HPA axis function and neuronal morphology plasticity in brain areas associated with emotional behavior.

Neuroinflammatory Pathways
--------------------------

Inflammation is a key mechanism in the pathophysiology of mood disorders, including major depression, post-partum depression and bipolar disorder ([@B45]; [@B29]). Increased levels of inflammatory factors, such as proinflammatory cytokines and chemokines, are found in a subset of depressed patients and may contribute to their symptoms through a direct effect in the brain ([@B184]). The mechanisms underlying inflammation and depression have been thoroughly reviewed elsewhere ([@B28]). Enhanced peripheral inflammation has also been reported in PTSD ([@B79]; [@B170]; [@B179]; [@B125]) and bipolar disorder ([@B81]; [@B68]; [@B105]; [@B220]). Importantly, inflammation has been proposed to be key in stress vulnerability and the pathogenesis of major depression ([@B155]).

Long chain ω3 PUFAs, DHA, and EPA and their derivatives, so-called SPMs, are well-known regulators of the inflammatory response ([@B198], [@B199]). More recently, DHA, EPA, and their derivatives have been shown to also regulate neuroinflammatory processes ([@B108]; [@B128]; [@B187]; [@B57]; [@B69]; [@B202]; recently reviewed in [@B121]). Briefly, the expression of the pro-inflammatory cytokine TNFα, IL-6, and IL-1β in the brain (triggered by peripheral or intracerebral administration of LPS, the Gram-negative bacteria endotoxin, amyloid beta administration or associated to aging) is decreased by DHA and EPA dietary supplementation ([@B114]; [@B173]; [@B49]; [@B94]). Importantly, in regards to the protective effect of EPA in depression, a dietary supplementation with this fatty acid decreased TNFα expression in the hippocampus following IL-1β central injection ([@B57]). *In vitro*, DHA, and EPA directly target microglia, the brain innate immune cell ([@B47]; [@B3]; [@B181]; [@B35]; [@B69]), however, a direct effect of these fatty acids on microglia *in vivo* has not been studied yet. In a model of multiple sclerosis induced by cuprizone, DHA/EPA promote the shift of microglia polarization toward a repair non-inflammatory phenotype ([@B37]). We have found that the brain content of ω3 PUFA, either increased through the diet or by genetic means, influences microglia and the related neuroinflammatory response to LPS ([@B158]; [@B135]; [@B52],[@B53]; [@B56]). In rodent models of neuroinflammation triggered by the intracerebral administration of amyloid-β or cuprizone, brain DHA decreases the number of activated microglia, but not of astrocytes ([@B94]), and promotes an anti-inflammatory phenotype of microglia ([@B37]). An acute intravenous administration of DHA reduces LPS-induced cytokine production in the hippocampus ([@B69]), but no significant effect of intravenously administered DHA was shown on microglia activation (measured by the upregulation of translocator protein TSPO by Positron-emission tomography) in the injured spinal chord of rat ([@B219]). DHA and EPA effect on neuroinflammatory pathways could be either direct or indirect. Indeed, LC-PUFAs are converted by COX, LOX, and CYP450 into SPMs, which display pro or anti-inflammatory activities ([@B39]), including in the brain ([@B173]; [@B187]; [@B121]). Eicosanoids, resolvins, protectin and maresin derived from DHA and EPA have anti-inflammatory and pro-resolving activities ([@B10]; [@B200]). On the opposite, SPMs derived from LA and AA (prostaglandins, leukotrienes or thromboxanes) are mostly pro-inflammatory ([@B23]). *In vitro*, DHA derivatives display anti-inflammatory activities in microglia ([@B140]; [@B131]; [@B173]; [@B187]). Brain inflammation triggered by the administration of LPS activates ω6 PUFA derived-prostaglandins production in the brain ([@B188]; [@B211]), together with the expression of the enzymes involved in the synthesis of SPMs ([@B188]; [@B211]). However, recent work showed that amyloid-β brain infusion, which is proinflammatory, did not increase brain SPMs production ([@B95]). Importantly, PUFAs dietary intervention can modulate cellular levels of both PUFAs and SPMs, with dietary ω6 PUFAs supplementation increasing AA-derived and decreasing EPA-derived SPMs ([@B212]). Conversely, LC ω3 PUFAs supplementation increasing EPA and DHA-derived SPMs ([@B8]; [@B86]) have not been consistently demonstrated ([@B95]). These observations reinforce the need for more studies to link nutritionnal interventions and SPMs production in specific brain regions.

As previously described, clinical trials using DHA and/or EPA showed mixed results on depressive symptoms. However, based on meta-analysis, EPA has been suggested as a predictor of mood disorder treatment efficiency ([@B142]; [@B208]; [@B160]). Such a positive effect of EPA could be linked to its anti-inflammatory activity. Indeed, in depressed patients, high EPA supplementation is more effective in those with inflammation ([@B185]). In particular, patients with high IL-1 receptor antagonist and C-reactive protein blood levels have greater improvement in mood symptoms in response to EPA, but not DHA enriched dietary supplement. Additional studies with a higher number of patients are warranted to confirm this interesting first study. In addition, whether the higher efficiency of high EPA rather of DHA dietary supplementation is linked to its specific effect on inflammation through specific SPMs remains to be investigated.

Conclusion and Future Directions
================================

As indicated above, the summarized literature indicate that low ω3 PUFAs intake may predispose certain individuals to depression and anxiety and that dietary supplementation with LC ω3 PUFAs represents an interesting strategy for preventing or treating depression and anxiety disorders in certain individuals. However, several important issues remain to be determined. One of those is the discordant results regarding outcomes in clinical nutritional interventions to investigate the effectiveness of ω3 PUFA supplementation on mood. The unmatched results seem to be partly due to the lack of standardization regarding important parameters such as (i) the inclusion criteria used, (ii) the PUFA composition of the fish oil as well as (iii) the nutritional baseline status of subjects, and (iv) the methods of diagnosis used. We are now beginning to understand how PUFAs affect our brain through a direct sensing effect or an indirect one. This review highlights that ω3 PUFAs, in particular DHA, act onto the brain through a direct effect on FFAR or other indirect mechanisms. We also discussed an indirect effect of ω3 PUFAs on eCB and the HPA axis systems as relevant mechanisms by which dietary ω3 PUFAs modulate mood-related behaviors. Although recent work suggest a causal relationship between nutritional ω3 PUFAs deficiency and alterations of these two systems, major questions remain unanswered, such as how dietary ω3 PUFA maintains HPA axis function to prevent emotional impairment. In this review, we highlighted how powerful dietary PUFAs are in the modulation of the eCB system, which is known to be intimately involved in the regulation of the HPA axis ([@B147]). As to whether these two mechanisms are interconnected in the effects of ω3 PUFA deficiency-induced depression is yet to be determined. In conclusion, this review reinforces the idea of the usefulness of the dietary ω3 PUFAs as an interesting tool for the design and testing of new non-pharmacological strategies in the treatment of neuropsychiatric disorders such as mood-related disease.
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